Steady-state plasma concentrations and effects of taxol for a 250 mg/m2 dose in combination with granulocyte-colony stimulating factor in patients with ovarian cancer

Carlos A. Jamis-Dow, Raymond W. Klecker, Gisele Sarosy, Eddie Reed, Jerry M. Collins

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

Taxol, a natural product initially isolated from the stem bark of the western yew Taxus brevifolia, is undergoing phase II and III evaluation due to its reported activity against a variety of tumors. Previous studies have described correlations between plasma concentrations and toxicity when taxol is given (a) at lower doses, (b) for shorter infusion times, and (c) without granulocyte-colonystimulating factor. Because the 24-h infusion schedule is most commonly used in current clinical trials, we attempted to correlate steady-state plasma concentrations of taxol achieved with a 24-h continuous i.v. infusion with toxicities and responses. Plasma samples from 48 refractory ovarian cancer patients were obtained 1-2 h prior to the end of the first taxol infusion. Taxol concentrations were measured by high-performance liquid chromatography (HPLC). Interpatient variation of taxol plasma concentrations was small (mean±SD, 0.85±0.21 μM. Total taxol body clearance was 256±72 ml min-1m-2 (mean±SD). Taxol plasma protein binding was 88.4%±1.3% (mean±SD, n=9). Grade 3-4 hematologic toxicity, mainly leukopenia, occurred in 92% of the patients. The leukopenia was transient and did not warrant a reduction in the dose of taxol. Grade 3-4 nonhematologic toxicity occurred in 8% of the patients. No severe hypersensitivity reaction or grade 3-4 neurotoxicity was observed. Correlations of plasma concentrations and toxicities were not feasible due to the high frequency of hematologic effects and the low frequency of nonhematologic toxicity. The low degree of interpatient variation in plasma concentrations hindered the development of correlations with response.

Original languageEnglish (US)
Pages (from-to)48-52
Number of pages5
JournalCancer Chemotherapy and Pharmacology
Volume33
Issue number1
DOIs
StatePublished - Jan 1 1993

Fingerprint

Granulocyte Colony-Stimulating Factor
Paclitaxel
Ovarian Neoplasms
Plasmas
Toxicity
Leukopenia
Taxus
High performance liquid chromatography
Biological Products
Granulocytes
Protein Binding
Refractory materials
Blood Proteins
Tumors
Appointments and Schedules
Hypersensitivity
High Pressure Liquid Chromatography
Clinical Trials

All Science Journal Classification (ASJC) codes

  • Oncology
  • Toxicology
  • Pharmacology
  • Cancer Research
  • Pharmacology (medical)

Cite this

Jamis-Dow, Carlos A. ; Klecker, Raymond W. ; Sarosy, Gisele ; Reed, Eddie ; Collins, Jerry M. / Steady-state plasma concentrations and effects of taxol for a 250 mg/m2 dose in combination with granulocyte-colony stimulating factor in patients with ovarian cancer. In: Cancer Chemotherapy and Pharmacology. 1993 ; Vol. 33, No. 1. pp. 48-52.
@article{53e755e586be47658a3068042f08c3bb,
title = "Steady-state plasma concentrations and effects of taxol for a 250 mg/m2 dose in combination with granulocyte-colony stimulating factor in patients with ovarian cancer",
abstract = "Taxol, a natural product initially isolated from the stem bark of the western yew Taxus brevifolia, is undergoing phase II and III evaluation due to its reported activity against a variety of tumors. Previous studies have described correlations between plasma concentrations and toxicity when taxol is given (a) at lower doses, (b) for shorter infusion times, and (c) without granulocyte-colonystimulating factor. Because the 24-h infusion schedule is most commonly used in current clinical trials, we attempted to correlate steady-state plasma concentrations of taxol achieved with a 24-h continuous i.v. infusion with toxicities and responses. Plasma samples from 48 refractory ovarian cancer patients were obtained 1-2 h prior to the end of the first taxol infusion. Taxol concentrations were measured by high-performance liquid chromatography (HPLC). Interpatient variation of taxol plasma concentrations was small (mean±SD, 0.85±0.21 μM. Total taxol body clearance was 256±72 ml min-1m-2 (mean±SD). Taxol plasma protein binding was 88.4{\%}±1.3{\%} (mean±SD, n=9). Grade 3-4 hematologic toxicity, mainly leukopenia, occurred in 92{\%} of the patients. The leukopenia was transient and did not warrant a reduction in the dose of taxol. Grade 3-4 nonhematologic toxicity occurred in 8{\%} of the patients. No severe hypersensitivity reaction or grade 3-4 neurotoxicity was observed. Correlations of plasma concentrations and toxicities were not feasible due to the high frequency of hematologic effects and the low frequency of nonhematologic toxicity. The low degree of interpatient variation in plasma concentrations hindered the development of correlations with response.",
author = "Jamis-Dow, {Carlos A.} and Klecker, {Raymond W.} and Gisele Sarosy and Eddie Reed and Collins, {Jerry M.}",
year = "1993",
month = "1",
day = "1",
doi = "10.1007/BF00686022",
language = "English (US)",
volume = "33",
pages = "48--52",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "1",

}

Steady-state plasma concentrations and effects of taxol for a 250 mg/m2 dose in combination with granulocyte-colony stimulating factor in patients with ovarian cancer. / Jamis-Dow, Carlos A.; Klecker, Raymond W.; Sarosy, Gisele; Reed, Eddie; Collins, Jerry M.

In: Cancer Chemotherapy and Pharmacology, Vol. 33, No. 1, 01.01.1993, p. 48-52.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Steady-state plasma concentrations and effects of taxol for a 250 mg/m2 dose in combination with granulocyte-colony stimulating factor in patients with ovarian cancer

AU - Jamis-Dow, Carlos A.

AU - Klecker, Raymond W.

AU - Sarosy, Gisele

AU - Reed, Eddie

AU - Collins, Jerry M.

PY - 1993/1/1

Y1 - 1993/1/1

N2 - Taxol, a natural product initially isolated from the stem bark of the western yew Taxus brevifolia, is undergoing phase II and III evaluation due to its reported activity against a variety of tumors. Previous studies have described correlations between plasma concentrations and toxicity when taxol is given (a) at lower doses, (b) for shorter infusion times, and (c) without granulocyte-colonystimulating factor. Because the 24-h infusion schedule is most commonly used in current clinical trials, we attempted to correlate steady-state plasma concentrations of taxol achieved with a 24-h continuous i.v. infusion with toxicities and responses. Plasma samples from 48 refractory ovarian cancer patients were obtained 1-2 h prior to the end of the first taxol infusion. Taxol concentrations were measured by high-performance liquid chromatography (HPLC). Interpatient variation of taxol plasma concentrations was small (mean±SD, 0.85±0.21 μM. Total taxol body clearance was 256±72 ml min-1m-2 (mean±SD). Taxol plasma protein binding was 88.4%±1.3% (mean±SD, n=9). Grade 3-4 hematologic toxicity, mainly leukopenia, occurred in 92% of the patients. The leukopenia was transient and did not warrant a reduction in the dose of taxol. Grade 3-4 nonhematologic toxicity occurred in 8% of the patients. No severe hypersensitivity reaction or grade 3-4 neurotoxicity was observed. Correlations of plasma concentrations and toxicities were not feasible due to the high frequency of hematologic effects and the low frequency of nonhematologic toxicity. The low degree of interpatient variation in plasma concentrations hindered the development of correlations with response.

AB - Taxol, a natural product initially isolated from the stem bark of the western yew Taxus brevifolia, is undergoing phase II and III evaluation due to its reported activity against a variety of tumors. Previous studies have described correlations between plasma concentrations and toxicity when taxol is given (a) at lower doses, (b) for shorter infusion times, and (c) without granulocyte-colonystimulating factor. Because the 24-h infusion schedule is most commonly used in current clinical trials, we attempted to correlate steady-state plasma concentrations of taxol achieved with a 24-h continuous i.v. infusion with toxicities and responses. Plasma samples from 48 refractory ovarian cancer patients were obtained 1-2 h prior to the end of the first taxol infusion. Taxol concentrations were measured by high-performance liquid chromatography (HPLC). Interpatient variation of taxol plasma concentrations was small (mean±SD, 0.85±0.21 μM. Total taxol body clearance was 256±72 ml min-1m-2 (mean±SD). Taxol plasma protein binding was 88.4%±1.3% (mean±SD, n=9). Grade 3-4 hematologic toxicity, mainly leukopenia, occurred in 92% of the patients. The leukopenia was transient and did not warrant a reduction in the dose of taxol. Grade 3-4 nonhematologic toxicity occurred in 8% of the patients. No severe hypersensitivity reaction or grade 3-4 neurotoxicity was observed. Correlations of plasma concentrations and toxicities were not feasible due to the high frequency of hematologic effects and the low frequency of nonhematologic toxicity. The low degree of interpatient variation in plasma concentrations hindered the development of correlations with response.

UR - http://www.scopus.com/inward/record.url?scp=0027504607&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027504607&partnerID=8YFLogxK

U2 - 10.1007/BF00686022

DO - 10.1007/BF00686022

M3 - Article

C2 - 7505722

AN - SCOPUS:0027504607

VL - 33

SP - 48

EP - 52

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 1

ER -